NIRF for Parathyroid Visualization: a Pilot Study
Thyroid Disease
About this trial
This is an interventional diagnostic trial for Thyroid Disease focused on measuring Near infrared fluorescence, ICG, Parathyroid gland
Eligibility Criteria
Inclusion Criteria:
- Male or female patients, aged 18 years and above
- Scheduled for elective total or hemi thyroidectomy
- Normal liver and renal function
- No known hypersensitivity for iodine or ICG
- Able to understand the nature of the study procedures
- Willing to participate and give written informed consent
Exclusion Criteria:
- Age < 18 years
- Liver or renal insufficiency
- Known ICG, iodine, penicillin or sulfa hypersensitivity
- Pregnancy or breastfeeding
- Not able to understand the nature of the study procedure
- i.v. heparin injection in the last 24h (LMWH not contraindicated)
- Not willing to participate
Sites / Locations
- Maastricht University Medical Center
Arms of the Study
Arm 1
Experimental
NIRF imaging in thyroid surgery
7.5 mg ICG is administered i.v. and the system will be switched to fluorescence mode. If needed, a second dose of 7.5 mg ICG can be administered. After identification of the parathyroid glands, surgery will continue until there is a desire to visualize the parathyroid glands again, another dose of ICG can be given. After complete removal of thyroid, another 7.5 mg of ICG will be given to assess the perfusion of the parathyroid gland. Directly after the procedure the researcher will ask the surgeon whether he/she thinks the technique is feasible. After surgery, the serum calcium levels will be determined in patients after total thyroidectomy on day 1, 2 and after two weeks. TSH will be determined after 2 weeks. The thyroid specimen will be send to pathology. In the specimen, the pathologist will search for parathyroid glands. Video recordings will be analyzed, quantifying the fluorescence signal compared to the background: measuring the TBR.